Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Bausch Health (BHC) has launched the syndication of new senior secured credit facilities totaling at least $3.8 billion, consisting of a 5-year $400 million senior secured revolving credit facility and a $3.4 billion 5.5-year secured term loan B facility. The transaction, led by JPMorgan Chase Bank, is part of a broader refinancing initiative to address near- and mid-term maturities.
The facilities will be secured by first-priority liens on the borrower's assets, including Bausch + Lomb equity interest. The company plans to use proceeds to repay existing credit agreements, redeem various senior secured and senior notes due between 2025-2028, and for general corporate purposes. Bausch Health reduced net debt by nearly $1 billion in 2024 and reports seven consecutive quarters of top- and bottom-line growth.
Bausch Health (NYSE:BHC) has launched a $4.0 billion senior secured notes offering due 2032 through its subsidiary 1261229 B.C. The company is also seeking to establish new senior secured credit facilities, including a $400 million 5-year revolving credit facility and a $3,400 million 5.5-year term loan facility.
The notes will be secured by first-priority liens on the issuer's assets, including Bausch + Lomb equity interest, and guaranteed by various company subsidiaries. The proceeds, combined with the new term loan facility, will be used to:
- Repay and terminate existing credit agreement
- Redeem all existing senior secured and senior notes due 2025-2028
- Pay related fees and expenses
- Fund general corporate purposes
The notes will be offered exclusively to qualified institutional buyers in the US and non-US persons outside the United States, with specific exemptions for Canadian securities laws.
Bausch Health Companies Inc. (NYSE/TSX:BHC) has announced an update regarding its financing initiatives, revealing the engagement of J.P. Morgan to assist with its previously disclosed financing objectives. The company emphasizes that any potential transactions are subject to market conditions and other factors, with no guarantee of successful completion on acceptable terms.
Bausch Health (BHC) reported strong financial results for Q4 and full-year 2024, marking its seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA. Fourth quarter revenues reached $2.56 billion, up 6% on a reported basis and 9% organically, while full-year revenues hit $9.63 billion, increasing 10% on a reported basis and 8% organically.
The company achieved Q4 GAAP Net Income of $93 million, though recorded a full-year net loss of $46 million. Consolidated Adjusted EBITDA grew 8% to $935 million in Q4 and 10% to $3.31 billion for the full year. All business segments showed growth, with particularly strong performance from Solta Medical (34% growth) and Bausch + Lomb (9% growth) in Q4.
Bausch Health Companies (NYSE/TSX: BHC) has announced its participation in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida. The event is scheduled for Monday, February 24, 2025, at 8:45 a.m. EST.
The company will provide a live audio webcast of the event, which will be accessible through the Investor Relations section of Bausch Health's website. Interested parties can access the webcast at http://ir.bauschhealth.com/events-and-presentations. A replay of the event will be made available on the same investor relations website after the conference.
Bausch Health (NYSE/TSX: BHC) and its GI business, Salix Pharmaceuticals, have announced their 2025 Salix Gastrointestinal Health Scholars Program. The initiative will provide ten scholarships of up to $10,000 each to students living with GI diseases who are pursuing higher education.
This marks the sixth consecutive year of the program, which supports students attending two- or four-year colleges, universities, or advanced vocational/technical schools for the 2025-2026 academic year. The scholarships are available in three categories: Undergraduate Scholar Awards, Graduate Scholar Awards, and Working and/or Single Parents Scholar Awards.
Applicants must complete an online application, submit reference letters, and write an essay about their GI condition's impact on their life and their healthcare provider's role. The application period closes on May 5, 2025, with winners to be announced in summer 2025.
Bausch Health (NYSE/TSX: BHC) has provided an update regarding the potential sale of its Bausch + Lomb subsidiary, which was initially disclosed in December 2024. During the second half of 2024, while exploring liability management alternatives, Bausch + Lomb received an acquisition offer from a private equity firm. However, both companies' boards determined the offer didn't reflect Bausch + Lomb's long-term value and decided not to proceed with the sale.
Bausch Health will maintain its 88% ownership stake in Bausch + Lomb and continue working on liability management alternatives, including new debt financing. The company highlighted strong business performance in 2024, having raised its full-year guidance for revenue, adjusted EBITDA, and adjusted operating cash flow in October 2024. Fourth quarter and full-year 2024 earnings, along with 2025 guidance, will be reported on February 19, 2025.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has scheduled the release of its fourth quarter and full year 2024 financial results for Wednesday, February 19, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. U.S. EST on the same day to discuss the results and provide a business update.
Interested parties can access all materials through the Investor Relations section of Bausch Health's website. A replay of the conference call will be made available on the investor relations website. To participate in the live Q&A session, participants must register in advance through the provided link.
Bausch Health (NYSE/TSX: BHC) announced that XIFAXAN® (rifaximin) 550 mg tablets has been selected by the Centers for Medicare and Medicaid Services (CMS) for the second round of price negotiations under the Inflation Reduction Act. The negotiated pricing will take effect in 2027.
The company plans to engage with CMS to demonstrate XIFAXAN's healthcare system value, highlighting recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), which gave XIFAXAN® their highest recommendation (Grade I, A,1) in practice guidelines.
Bausch Health Companies (NYSE/TSX: BHC) has confirmed it is exploring potential sale options for its subsidiary Bausch + Lomb (NYSE/TSX: BLCO) as one of several alternatives to complete their separation. The statement was issued in response to a request from the Canadian Investment Regulatory Organization (CIRO) due to stock volatility concerns related to market rumors.
The company emphasized that while the Board of Directors has authorized management to explore a potential sale, no decision has been made to proceed with any particular transaction, and there is no guarantee that the process will result in a deal. The company stated it will not provide additional details until further disclosure becomes appropriate or necessary.